Medicineen
Australian Researchers Advance Novel Motor Neurone Disease Therapy to Phase 2 Trial
The protein-based treatment NUN-004 aims to protect motor neurons and encourage nerve repair in patients with MND.


PENN Explainer
Hear this story explained in 90 seconds.
A new protein-based therapy designed to treat motor neurone disease (MND) is moving into a national Phase 2 clinical trial in Australia. The treatment, known as NUN-004, was developed through more than 25 years of research at The University of Queensland's Queensland Brain Institute. The biotechnology company NuNerve is now leading the effort to test the therapy in a group of 75 participants. This study marks a significant step in the effort to find treatments that go beyond simply slowing the progression of the disease.
Emeritus Professor Perry Bartlett, who serves as the chair of NuNerve, explained that the therapy targets a specific receptor called EphA4. Excessive signaling from this receptor has been linked to the degeneration of motor neurons and the failure of nerve connections to recover. By inhibiting this receptor, the researchers hope to protect existing neurons and create an environment where damaged neural connections can repair themselves. This approach represents a more ambitious goal than current standard treatments, which primarily focus on slowing the loss of physical function.
"No approved treatment has been shown to halt or reverse progression across the broad MND population," said Professor Bartlett. He noted that current medical options are largely limited to managing the decline of patients. The development of NUN-004 is the result of decades of work focused on understanding the biology of EphA4 and its role in the nervous system. The team believes this rigorous testing phase will provide the necessary data to determine if the therapy can meaningfully change the course of the disease.
Clinical trials for the therapy will take place across six different sites in Australia. These locations include facilities in the Sunshine Coast, Sydney, Newcastle, Brisbane, and Perth. Researchers plan to monitor a variety of metrics to evaluate the drug's effectiveness. These include changes in patient function, safety, and tolerability, as well as respiratory and neurophysiological assessments.
Associate Professor Antony Winkel, the clinical lead for NuNerve, emphasized the importance of the study's design. The trial will combine measures of everyday physical function with biomarker assessments to see if early positive signals from Phase 1 testing translate into a real treatment effect. If the findings are confirmed, they could provide a new option for people living with MND. The researchers hope this work will also highlight the impact of Australian medical research on the international stage.
You've reached your free article limit
You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.
Already a subscriber? Sign in.
Ask the Author
Subscribers can ask the journalist a question about this story. Subscribe to ask.
Neutrality note
Auto-harvested from global news wires and presented neutrally by PENN.
to vote
Comments
No comments yet — be the first to share your thoughts.



